“Patients with the highest levels of vitamin D have a 21% improvement in progression-free survival,” Dr. Ng added. The study showed that male and black patients, those with lower dietary and supplemental vitamin D intake, patients living in the northeast, patients with an ECOG performance status 1, patients with tumoral RAS mutation, patients with higher BMI, and patients with lower physical activity had significantly lower levels of vitamin D with a median plasma vitamin D level of 17.2ng/mL among all patients.

A randomized, phase II trial to assess the effect of vitamin D supplementation in patients with metastatic colorectal cancer receiving FOXLOX plus bevacizumab is currently ongoing.